VPC
ELVN icon

Vestal Point Capital’s Enliven Therapeutics ELVN Stock Holding History

Vestal Point Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203M Buy
4,000,000
+750,000
+23% +$31.8M 4.74% 5
2026
Q1 		$127M Sell
3,250,000
-580,000
-15% -$16.1M 3.56% 6
2025
Q4 		$59M Buy
3,830,000
+2,670,000
+230% +$53.2M 2.01% 17
2025
Q3 		$23.7M Buy
1,160,000
+910,000
+364% +$18.3M 1.07% 34
2025
Q2 		$5.01M Buy
+250,000
New +$4.73M 0.26% 52

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vestal Point Capital's ELVN Position: Q2 2026 in Review

Vestal Point Capital increased its Enliven Therapeutics (ELVN) stake by 23% in Q2 2026, buying an estimated $31.8M and bringing the position to 4,000,000 shares worth $203M. The position accounts for 4.74% of the portfolio, ranked #5.

Vestal Point Capital first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Vestal Point Capital held 4,000,000 shares of Enliven Therapeutics worth $203M as of Q2 2026.
  • Vestal Point Capital bought 750,000 Enliven Therapeutics shares in Q2 2026, an estimated $31.8M.
  • Enliven Therapeutics made up 4.74% of Vestal Point Capital's portfolio in Q2 2026, its #5 holding.
  • Vestal Point Capital first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.